Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma (ASCO 2011 Melanoma, Abstract LBA4)

P. Lorigan; P. B. Chapman; A. Hauschild; C. Robert; J. M. Larkin; J. B. Haanen; A. Ribas; D. Hogg; S O'Day; P. A. Ascierto; A. Testori; R. Dummer; J. A. Sosman; C. Garbe; R. J. Lee; K. B. Nolop; B. Nelson; J. Hou; K. T. Flaherty; G. A. McArthur

Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma (ASCO 2011 Melanoma, Abstract LBA4)

P. Lorigan
, P. B. Chapman
, A. Hauschild
, C. Robert
, J. M. Larkin
, J. B. Haanen
, A. Ribas
, D. Hogg
, S O'Day
, P. A. Ascierto
, A. Testori
, R. Dummer
, J. A. Sosman
, C. Garbe
, R. J. Lee
, K. B. Nolop
, B. Nelson
, J. Hou
, K. T. Flaherty
, G. A. McArthur

Research output: Contribution to conference › Abstract

Original language	English
Publication status	Published - 2011
Event	ASCO - Chicago, USA Duration: 2 Jun 2011 → 6 Jun 2011

Conference

Conference	ASCO
City	Chicago, USA
Period	2/06/11 → 6/06/11

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

Lorigan, P., Chapman, P. B., Hauschild, A., Robert, C., Larkin, J. M., Haanen, J. B., Ribas, A., Hogg, D., O'Day, S., Ascierto, P. A., Testori, A., Dummer, R., Sosman, J. A., Garbe, C., Lee, R. J., Nolop, K. B., Nelson, B., Hou, J., Flaherty, K. T., & McArthur, G. A. (2011). Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma (ASCO 2011 Melanoma, Abstract LBA4). Abstract from ASCO, Chicago, USA.

@conference{c2dd844bbd114d98b16ac3ccc82d82d8,

title = "Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma (ASCO 2011 Melanoma, Abstract LBA4)",

author = "P. Lorigan and Chapman, \{P. B.\} and A. Hauschild and C. Robert and Larkin, \{J. M.\} and Haanen, \{J. B.\} and A. Ribas and D. Hogg and S O'Day and Ascierto, \{P. A.\} and A. Testori and R. Dummer and Sosman, \{J. A.\} and C. Garbe and Lee, \{R. J.\} and Nolop, \{K. B.\} and B. Nelson and J. Hou and Flaherty, \{K. T.\} and McArthur, \{G. A.\}",

year = "2011",

language = "English",

note = "ASCO ; Conference date: 02-06-2011 Through 06-06-2011",

}

Lorigan, P, Chapman, PB, Hauschild, A, Robert, C, Larkin, JM, Haanen, JB, Ribas, A, Hogg, D, O'Day, S, Ascierto, PA, Testori, A, Dummer, R, Sosman, JA, Garbe, C, Lee, RJ, Nolop, KB, Nelson, B, Hou, J, Flaherty, KT & McArthur, GA 2011, 'Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma (ASCO 2011 Melanoma, Abstract LBA4)', ASCO, Chicago, USA, 2/06/11 - 6/06/11.

TY - CONF

T1 - Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma (ASCO 2011 Melanoma, Abstract LBA4)

AU - Lorigan, P.

AU - Chapman, P. B.

AU - Hauschild, A.

AU - Robert, C.

AU - Larkin, J. M.

AU - Haanen, J. B.

AU - Ribas, A.

AU - Hogg, D.

AU - O'Day, S

AU - Ascierto, P. A.

AU - Testori, A.

AU - Dummer, R.

AU - Sosman, J. A.

AU - Garbe, C.

AU - Lee, R. J.

AU - Nolop, K. B.

AU - Nelson, B.

AU - Hou, J.

AU - Flaherty, K. T.

AU - McArthur, G. A.

PY - 2011

Y1 - 2011

M3 - Abstract

T2 - ASCO

Y2 - 2 June 2011 through 6 June 2011

ER -